Pravastatin Actavis

País: Nova Zelândia

Língua: inglês

Origem: Medsafe (Medicines Safety Authority)

Ingredientes ativos:

Pravastatin sodium 20mg;  

Disponível em:

Teva Pharma (New Zealand) Limited

DCI (Denominação Comum Internacional):

Pravastatin sodium 20 mg

Dosagem:

20 mg

Forma farmacêutica:

Tablet

Composição:

Active: Pravastatin sodium 20mg   Excipient: Croscarmellose sodium Iron oxide yellow Lactose monohydrate Light magnesium oxide Magnesium stearate Microcelac 100 Povidone

Tipo de prescrição:

Prescription

Fabricado por:

Biocon Limited

Indicações terapêuticas:

In hypercholesterolemic patients without clinically evident coronary heart disease, Pravastatin Actavis is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. Pravastatin Actavis is indicated for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. Pravastatin Actavis is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.

Resumo do produto:

Package - Contents - Shelf Life: Blister pack, Alu-Alu blister pack with cardboard carton secondary packaging - 30 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture

Data de autorização:

2014-01-20